Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stake Lifted by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 763.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,753 shares of the company’s stock after buying an additional 1,550 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Intellia Therapeutics were worth $39,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its holdings in shares of Intellia Therapeutics by 5.5% during the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after acquiring an additional 606,507 shares during the period. Vanguard Group Inc. grew its position in Intellia Therapeutics by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Intellia Therapeutics by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after buying an additional 98,865 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC raised its holdings in shares of Intellia Therapeutics by 8.4% during the first quarter. Chevy Chase Trust Holdings LLC now owns 1,074,610 shares of the company’s stock valued at $29,563,000 after buying an additional 83,435 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTLA has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus dropped their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $21.00 on Friday. Intellia Therapeutics, Inc. has a 12 month low of $19.21 and a 12 month high of $34.87. The company has a market capitalization of $2.03 billion, a P/E ratio of -3.92 and a beta of 1.77. The company’s 50 day simple moving average is $22.73 and its 200 day simple moving average is $23.85.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. The business’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.40) earnings per share. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.